Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...
The pharmaceutical giant's climb in operational and financial quality arrives as President Donald Trump pledges to drive "fat-loss drug" prices much lower—a move that sent shares of major GLP-1 ...
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly ...
It has a couple of GLP-1 products that account for more than half of its top line. Competition in this space has been on the rise, including from top pharma companies. Whether it can continue rallying ...
It has a couple of GLP-1 products that account for more than half of its top line. Competition in this space has been on the rise, including from top pharma companies. Eli Lilly (NYSE: LLY) is the ...
With five games down, we’re starting to get an idea of which Michigan high school football teams are truly the best in the state. WDIV has teamed up with STATE CHAMPS! Sports Network to bring you a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eli Lilly's CEO reveals the ...
HOUSTON — It's official: Big Pharma is landing in Houston. Eli Lilly and Co. (NYSE: LLY) confirmed Sept. 23 that the Bayou City will be part of its domestic manufacturing push. David Ricks, Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback